Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.
Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.Across the 68 markets, sales ...
A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...
Research shows bimagrumab may prevent muscle and bone loss associated with weight loss medications like Wegovy, offering hope ...
18h
Hosted on MSNAscletis announces positive results in Phase Ib oral GLP-1RA trialThe Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.
Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...
Glucagon-like peptide-1 (GLP-1) is a well-known medication used by physicians to treat Type 2 diabetes. GLP-1 has also become ...
Immunic (IMUX) announced that IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6, demonstrated a ...
3d
News Medical on MSNDiabetes drugs may boost brain health but experts warn of risksRAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent ...
Dr. Corey L. Hartman tells ESSENCE how this prescription can have long-term effects not just the body—but also on our skin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results